Clinical Trials · NCT03447132
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- International Cancer Research Group, United Arab Emirates
- Enrollment
- 354
- Start date
- Dec 2017
- Locations
- 14 sites, 8 countries
- Primary endpoint
- pCR according to Le Chevalier's classification